QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
14 Abril 2023 - 7:00AM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of QIAseq Targeted cfDNA Ultra Panels that will enable
researchers studying cancer and other diseases to turn cell-free
DNA (cfDNA) liquid-biopsy samples into libraries ready for
next-generation sequencing (NGS) in less than eight hours.
The new kit adds another innovation to the
QIAseq Targeted DNA product portfolio. It will be one of the
central features of QIAGEN’s life-science offering at the 2023
annual meeting of the American Association for Cancer Research
(AACR) in Orlando, Florida, from April 14 to 19, 2023.
Liquid biopsy centered on cfDNA has become a
vital tool in the diagnosis, outcome prognosis and treatment
monitoring of cancer and other diseases. Carried by blood and other
body fluids, cfDNA eliminates the need for surgery to take tissue
samples. But it often carries disease-relevant variants in low
concentrations, which means researchers demand extremely sensitive
and reliable tools.
The QIAseq Targeted cfDNA Ultra Panels meet this
requirement as they enable reliable detection of somatic genetic
variants in challenging detection scenarios as low as 0.1% variant
allele frequency (VAF) by enhanced chemistry, reduced enzymatic
error rates, and an optimized bioinformatics pipeline.
“QIAGEN is dedicated to driving innovation in
liquid biopsy technology to enhance cancer research and improve
patient outcomes. With the launch of our QIAseq Targeted cfDNA
Ultra Panels, researchers can now rapidly and accurately detect
somatic genetic variants at low concentrations, providing a
valuable tool for investigation of cancer and other diseases,” said
Dr. Thomas Schweins, Senior Vice President and Head of QIAGEN’s
Life Sciences Business Area. “We are delighted to engage with
experts at AACR 2023 and demonstrate our many contributions to
fighting cancer.”
The proven ability of QIAGEN technology to
detect tiny traces cfDNA variants will feature in the AACR’s
Spotlight Theater Talks from 10-11 a.m. on April 17. Marzia Del Re
from the University of Pisa, Italy, will present her study of
QIAGEN’s QIAcuity nanoplate-based digital PCR and other systems.
“Our data show QIAcuity has a higher sensitivity than droplet
digital PCR,” she said. “This allows the detection of a larger
number of mutated patients, even with low cfDNA abundance.”
The QIAcuity digital PCR system enables
researchers to detect and quantify DNA and RNA targets with high
precision and sensitivity, allowing for reliable analysis of rare
and difficult-to-detect targets for a wide range of applications.
The instruments integrate partitioning, thermocycling and imaging
into one workflow, cutting processing times to only two hours.
QIAGEN will also add new pan-cancer panels to
its digital PCR portfolio. These panels offer a cutting-edge
solution for the investigation of the most important cancer-related
genes and will be available to customers starting in fall 2023.
With a focus on hallmark mutations within specific genes, these
assays enable researchers to investigate samples in multiplex
reactions, allowing for faster and more efficient analysis. The
panels are suitable for a range of applications, including
biomarker validation, orthogonal validation of next-generation
sequencing, resistance monitoring, drug monitoring, and tumor
characterization.
QIAcuity’s extremely reliable mutation detection
can be coupled with the easy sample processing of QIAGEN’s EZ2
Connect system. The platform for fully automated and convenient
sample processing purifies DNA and RNA from various sample types
using prefilled reagent-cartridges, contributing to optimized
workflows and greater lab productivity. QIAcuity ensures fast and
sensitive ultra-low mutation detection – a ground-breaking
end-to-end combination for cancer researchers.
QIAGEN is looking forward to hosting AACR
attendees at booth #753 in Orlando’s Orange County Convention
Center. It will here unveil QIAcube Connect Red, a limited edition
of QIAGEN’s gold-standard automated device for DNA, RNA and protein
sample processing. Over 10,000 QIAcube instruments with blue trims
have been installed – but there will always only be 100 devices
with a red door-trim.
Learn more about QIAGEN’s commitment to fighting
cancer at www.qiagen.com/conquer-cancer.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare), Applied Testing (primarily
forensics), Pharma (pharma and biotech companies) and Academia
(life sciences research). As of December 31, 2022, QIAGEN
employed approximately 6,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, collaborations
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission
(SEC).
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Eltrop
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024